Forum Topic News
  • Conversation: US approves UCB’s Cimzia for psoriasis

    • May 29, 2018 12:55 PM BST
      • Post(s)

      US approves UCB’s Cimzia for psoriasis

      US regulators have expanded the reach of UCB’s Cimzia, allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
      The anti-inflammatory is already on the market for use in rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis and axial spondyloarthritis.
      This latest approval makes Cimzia (certolizumab pegol) the first Fc-free, PEGylated anti-TNF treatment option for this indication and marks UCB’s entry into immuno-dermatology, “where significant unmet need currently exists,” the Beligian drugmaker noted.
      The drug’s expanded label rides on the back of positive data from a Phase III clinical development programme consisting of CIMPASI-1, CIMPASI-2 and CIMPACT trials, which enrolled over 1,000 patients, of whom nearly one third had prior biologic exposure.
      Read more:

Add Reputation

Do you want to add reputation for this member by this post?

or cancel